Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

0.7036 +0.0623 (+9.71%)
Delayed Quote Updated: 2:12 PM EDT, Oct 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,556,565
Open 0.6260
Bid (Size) 0.6960 (400)
Ask (Size) 0.7049 (600)
Prev. Close 0.6413
Today's Range 0.5982 - 0.7501
52wk Range 0.6250 - 4.340
Shares Outstanding 11,184,423
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Powering the AI Economy: New to The Street Show #776 Premieres Tonight on Bloomberg Television
The Show Broadcasts Across the U.S., Latin America, Southeast Asia and MENA as Sponsored Programming 
From New to The Street
Via ACCESS Newswire
News headline image
New to The Street Show 775 Premieres Tonight on Bloomberg Television Across the United States, Latin America, MENA and Southeast Asia, Featuring American Fusion, HPB, T-REX Acquisition Corp. and SyncMeOn
Fusion energy, solid-state batteries, digital-asset infrastructure and AI-era restaurant procurement lead a four-region broadcast, with commercials from BioVie, Lantern Pharma, Big Sky Industrial and... 
From New to The Street
Via ACCESS Newswire

Performance

52-Week Range 83.8% below 52-week high
0.7036
0.6252W Low 4.3452W High
1 Week 12.1% below 1-week high
0.621W Low 0.801W High

Lantern Pharma Inc. - Common Stock (LTRN) traded between $0.62 and $4.34 over the past 52 weeks and last traded at $0.70, 83.8% below its 52-week high. Over the past week it ranged between $0.62 and $0.80.

Past 12 Months
-1.0%
-53.1%
-76.1%
-74.5%
-77.4%
-82.9%
1W -$0.01
1M -$0.80
3M -$2.25
6M -$2.06
YTD -$2.41
1Y -$3.41

LTRN was -82.9% over the past year, -74.5% over six months, -77.4% year to date, -1.0% in the last week.

12 Months vs Market
LTRN
-82.9%
DIA
+12.2%
SPY
+14.6%
QQQ
+17.6%
IWM
+11.2%

Over the past 12 months LTRN returned -82.9% versus DIA (Dow) +12.2%, SPY (S&P 500) +14.6%, QQQ (Nasdaq 100) +17.6% and IWM (Russell 2000) +11.2%.

Volume & Liquidity 8.40× 3-mo avg
Today 1,556,565 3-mo avg 185.4K
1W
194.7K
1M
310.8K
3M
185.4K
6M
212.9K
YTD
310.2K
1Y
264.2K

LTRN most recently traded 1,556,565 shares against a 3-month average daily volume of 185.4K.

More News

Read More
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present at ThinkEquity Conference on Oct. 15
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Receives Taiwan Approvals to Advance Phase 2 HARMONIC(TM) Trial
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
From Lantern Pharma Inc.
Via Business Wire
NetworkNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Closes $4 Million Registered Direct Offering
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
From Lantern Pharma Inc.
Via Business Wire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Announces $4 Million Registered Direct Offering
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global
From New to The Street
Via ACCESS Newswire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present Open-Medicine AI Growth Plan, Live Platform Demo in Webinar
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
From Lantern Pharma Inc.
Via Business Wire
MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
From New to The Street
Via ACCESS Newswire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) to Host Webinar on Open-Medicine AI Platform, Business Model and Development Roadmap
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Show 771 Airs Today on Bloomberg, Featuring Bill Mobley, Panna Sharma, Phillip Toppino and Dr. Kelley Gurley
From New to The Street
Via ACCESS Newswire
News headline image
New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)
From New to The Street
Via ACCESS Newswire
News headline image
New to The Street Broadcasting Today at 6:30 PM EST on Bloomberg Television Across the U.S., Latin America and MENA-Featuring FreeCast (NASDAQ: CAST), Metaterra Holdings (MTHI) and SafeSpace Global (SGCC)
From New to The Street
Via ACCESS Newswire
News headline image
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
NetworkNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Advances AI-Driven Oncology Pipeline, Establishes Open Medicine AI
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results
From New to The Street
Via ACCESS Newswire

Frequently Asked Questions

Is Lantern Pharma Inc. - Common Stock publicly traded?
Yes, Lantern Pharma Inc. - Common Stock is publicly traded.
What exchange does Lantern Pharma Inc. - Common Stock trade on?
Lantern Pharma Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lantern Pharma Inc. - Common Stock?
The ticker symbol for Lantern Pharma Inc. - Common Stock is LTRN on the Nasdaq Stock Market
What is the current price of Lantern Pharma Inc. - Common Stock?
The current price of Lantern Pharma Inc. - Common Stock is 0.7036
When was Lantern Pharma Inc. - Common Stock last traded?
The last trade of Lantern Pharma Inc. - Common Stock was at 10/20/26 02:12 PM ET
What is the market capitalization of Lantern Pharma Inc. - Common Stock?
The market capitalization of Lantern Pharma Inc. - Common Stock is 7.87M
How many shares of Lantern Pharma Inc. - Common Stock are outstanding?
Lantern Pharma Inc. - Common Stock has 8M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.